Welcome to our dedicated page for Orthofix Med SEC filings (Ticker: OFIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Orthofix Medical Inc. (NASDAQ: OFIX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Orthofix is a global medical technology company focused on spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, and its filings offer detailed insight into these operations.
Orthofix uses current reports on Form 8-K to announce material events such as quarterly financial results, non-GAAP financial measure discussions, and outcomes of its annual meeting of shareholders. Recent 8-K filings describe how the company reports net sales by category, including Bone Growth Therapies, Spinal Implants, Biologics and Enabling Technologies, Global Spine and Global Orthopedics, and explain non-GAAP measures like constant currency, free cash flow, adjusted gross profit, adjusted net income (loss) and adjusted EBITDA.
Through SEC filings, Orthofix also discloses information on topics such as restructuring costs and impairments related to its M6 artificial disc product lines, merger-related costs associated with SeaSpine, and other adjustments that management excludes when evaluating underlying performance. Governance-related filings, including those covering the annual meeting, document director elections, advisory votes on executive compensation, auditor ratification and board committee appointments.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand segment reporting, non-GAAP adjustments, capital structure details and governance decisions. Users can monitor new 8-Ks and other forms as they are posted to EDGAR, and use the summaries to navigate Orthofix’s financial and regulatory history more efficiently.
Orthofix Medical Inc. (OFIX) filed a Form 8-K reporting the results of its 18 June 2025 Annual Meeting of Shareholders.
Quorum: 35,364,307 of 39,180,306 eligible shares were present, comfortably exceeding the 19,590,154-share quorum requirement.
Director elections: All ten nominees—Alan L. Bazaar, Wayne Burris, Massimo Calafiore, Vickie L. Capps, Michael M. Finegan, Jason M. Hannon, John B. Henneman III, Charles R. Kummeth, Shweta Singh Maniar and Michael E. Paolucci—were elected for one-year terms ending at the 2026 meeting. Each candidate received substantially more “For” than “Against” votes.
Say-on-Pay: The advisory resolution approving executive compensation passed with 30,003,045 votes in favour versus 610,731 against and 9,569 abstentions.
Auditor ratification: Shareholders ratified Ernst & Young LLP as independent auditor for fiscal 2025 (35,017,551 votes in favour; 329,289 against; 17,467 abstentions).
Board committee appointments: Effective immediately, the Board unanimously appointed director Vickie L. Capps to the Audit & Finance Committee and to the Compensation & Talent Development Committee.
The filing contains no financial results, strategic transactions or other material events beyond routine governance disclosures.